Top-Rated StocksTop-Rated Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis $16.65 -0.15 (-0.89%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$16.51▼$17.0050-Day Range$11.39▼$16.8052-Week Range$11.22▼$29.86Volume1.46 million shsAverage Volume1.15 million shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/APrice Target$35.09 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Syndax Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside110.8% Upside$35.09 Price TargetShort InterestBearish15.25% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.97) to ($3.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector429th out of 940 stocksBiotechnology Industry9th out of 27 stocks 4.5 Analyst's Opinion Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.09, Syndax Pharmaceuticals has a forecasted upside of 110.8% from its current price of $16.65.Amount of Analyst CoverageSyndax Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.25% of the outstanding shares of Syndax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently increased by 6.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Syndax Pharmaceuticals is -1.12. Previous Next 2.0 News and Social Media Coverage News SentimentSyndax Pharmaceuticals has a news sentiment score of -0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Syndax Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest16 people have searched for SNDX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows8 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Syndax Pharmaceuticals is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to decrease in the coming year, from ($2.97) to ($3.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -6.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -6.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Read More SNDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNDX Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comSyndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual MeetingDecember 3, 2023 | benzinga.comSyndax Pharmaceuticals Stock (NASDAQ:SNDX) Dividends: History, Yield and DatesDecember 10, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 21, 2023 | finance.yahoo.comSyndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual MeetingNovember 7, 2023 | finance.yahoo.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Could Be 49% Below Their Intrinsic Value EstimateNovember 7, 2023 | finance.yahoo.comSyndax Announces Participation at Stifel Healthcare ConferenceNovember 6, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Health Drive Buy Rating for Syndax PharmaceuticalsNovember 6, 2023 | markets.businessinsider.comPromising Pipeline Developments and Upcoming Approvals Bolster Buy Rating for Syndax PharmaceuticalsDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 4, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cencora (COR), Syndax Pharmaceuticals (SNDX) and AMN Healthcare Services (AMN)November 3, 2023 | markets.businessinsider.comMaintained Buy Rating on Syndax Pharmaceuticals: Promising Clinical Profiles and Consistent Cash FlowNovember 3, 2023 | finance.yahoo.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finance.yahoo.comSyndax Pharmaceuticals Inc (SNDX) Reports Q3 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comSyndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual MeetingNovember 2, 2023 | finance.yahoo.comSyndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual MeetingOctober 28, 2023 | finance.yahoo.comBank of America Says Contrarian Buy Signal Could Push Stocks Higher; Here Are 2 Names the Banking Giant Likes Right NowOctober 27, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Quest Diagnostics (DGX) and Syndax Pharmaceuticals (SNDX)October 27, 2023 | msn.comStifel Maintains Syndax Pharmaceuticals (SNDX) Buy RecommendationOctober 26, 2023 | finance.yahoo.comSyndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023October 25, 2023 | msn.comB of A Securities Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy RecommendationOctober 24, 2023 | finance.yahoo.comSyndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review ProgramOctober 17, 2023 | markets.businessinsider.comAnalyst Ratings for Syndax PharmaceuticalsOctober 13, 2023 | seekingalpha.comSyndax: Biotech To Watch With Regulatory Filings Before End Of 2023October 12, 2023 | msn.comGoldman Sachs Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy RecommendationOctober 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Teladoc (TDOC)October 3, 2023 | markets.businessinsider.comSyndax Pharmaceuticals Receives Buy Rating Following Promising AUGMENT-101 Study Results for Revumenib in Acute Leukemia TreatmentOctober 2, 2023 | proactiveinvestors.comSyndax Pharmaceuticals shares fall despite positive leukemia trialSee More Headlines Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNDX CUSIPN/A CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees107Year FoundedN/APrice Target and Rating Average Stock Price Target$35.09 High Stock Price Target$43.00 Low Stock Price Target$28.00 Potential Upside/Downside+110.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-149,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.37% Return on Assets-39.40% Debt Debt-to-Equity RatioN/A Current Ratio9.73 Quick Ratio9.73 Sales & Book Value Annual Sales$139.71 million Price / Sales8.30 Cash FlowN/A Price / Cash FlowN/A Book Value$7.76 per share Price / Book2.15Miscellaneous Outstanding Shares69,640,000Free Float66,368,000Market Cap$1.16 billion OptionableOptionable Beta1.07 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Michael A. Metzger M.B.A. (Age 52)CEO & Director Comp: $1.05MMr. Keith Alan Goldan CPA (Age 52)CFO, Treasurer & Chief Accounting Officer Comp: $649.07kMr. Luke J. Albrecht (Age 43)Senior VP, General Counsel & Secretary Comp: $605.82kDr. Catherine Madigan M.D. (Age 51)Chief Medical Officer Comp: $764.41kMr. Steve M. Sabus (Age 57)Chief Commercial Officer Comp: $523.44kDr. Peter Ordentlich B.Sc. (Age 54)Ph.D., Co-Founder & Chief Scientific Officer Dr. Richard A. Heyman Ph.D. (Age 66)Co-Founder Dr. Ronald M. Evans Ph.D. (Age 74)Co-Founder, Advisor and Chair of Scientific Advisory Board Dr. Michael Downes Ph.D.Co-FounderSharon KlahreVice President of Investor Relations & CommunicationsMore ExecutivesKey CompetitorsArdelyxNASDAQ:ARDXArcus BiosciencesNYSE:RCUSBelite BioNASDAQ:BLTEProtagonist TherapeuticsNASDAQ:PTGXKiniksa PharmaceuticalsNASDAQ:KNSAView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPBought 761,186 shares on 12/7/2023Ownership: 1.775%Wellington Management Group LLPBought 198,262 shares on 12/1/2023Ownership: 10.974%Deutsche Bank AGBought 6,037 shares on 11/24/2023Ownership: 0.072%GTS Securities LLCBought 42,800 shares on 11/16/2023Ownership: 0.000%Tudor Investment Corp Et AlBought 29,939 shares on 11/16/2023Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions SNDX Stock Analysis - Frequently Asked Questions Should I buy or sell Syndax Pharmaceuticals stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNDX shares. View SNDX analyst ratings or view top-rated stocks. What is Syndax Pharmaceuticals' stock price target for 2024? 10 analysts have issued 12 month price objectives for Syndax Pharmaceuticals' shares. Their SNDX share price targets range from $28.00 to $43.00. On average, they expect the company's share price to reach $35.09 in the next year. This suggests a possible upside of 110.8% from the stock's current price. View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts. How have SNDX shares performed in 2023? Syndax Pharmaceuticals' stock was trading at $25.45 on January 1st, 2023. Since then, SNDX shares have decreased by 34.6% and is now trading at $16.65. View the best growth stocks for 2023 here. When is Syndax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our SNDX earnings forecast. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07. What ETFs hold Syndax Pharmaceuticals' stock? ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Simplify Health Care ETF (PINK). What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU). When did Syndax Pharmaceuticals IPO? (SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (10.97%), Avidity Partners Management LP (4.05%), Jennison Associates LLC (3.38%), Hudson Bay Capital Management LP (1.78%), Adage Capital Partners GP L.L.C. (1.44%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith A Goldan, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich, Pierre Legault and William Meury. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SNDX) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.